AmCad BioMed Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Yi-Li Lee

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	1.5yrs

Son yönetim güncellemeleri

Recent updates

Companies Like AmCad BioMed (GTSM:4188) Are In A Position To Invest In Growth

Apr 19

AmCad BioMed (GTSM:4188) Is In A Good Position To Deliver On Growth Plans

Jan 04

CEO

Yi-Li Lee

no data

Görev süresi

NT$146,000

Tazminat

Ms. Yi-Li Lee serves as Chairman and President at AmCad BioMed Corporation. She serves as Vice President of Credit Agricole Corporate and Investment Bank. Ms. Lee serves as Senior Deputy General Manager of...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yi-Li Lee	Chairman & President	no data	NT$146.00k	Veri yok
Chen-Chia Lee	Director	no data	Veri yok	Veri yok
Yujia Li	Supervisor	no data	NT$45.00k	Veri yok
Jinjian Zhang	Supervisor	no data	NT$45.00k	4.58% NT$ 60.7m
Junheng Liao	Supervisor	no data	NT$25.00k	Veri yok
Weng-Foung Huang	Independent Director	no data	Veri yok	Veri yok
Yi-Ling Lee	Vice Chairman	4yrs	Veri yok	Veri yok
Tsay-Ping Wang	Director	1.5yrs	Veri yok	Veri yok
She-Yi Lin	Independent Director	1.5yrs	Veri yok	Veri yok
Hsueh-Yu Li	Independent Director	1.5yrs	Veri yok	Veri yok

1.5yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: 4188 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.5 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

AmCad BioMed Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

AmCad BioMed Corporation Announces Change of the Corporate Governance Officer

AmCad BioMed Corporation, Annual General Meeting, Jun 26, 2024

AmCad BioMed Corporation Announces Management Changes

AmCad Biomed Corporation Appoints Maureen Chang as Corporate Governance Officer

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: NT$0.30 loss per share (vs NT$0.20 loss in 3Q 2023)

AmCad BioMed Corporation to Report Q3, 2024 Results on Oct 31, 2024

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: NT$0.19 loss per share (vs NT$0.24 loss in 2Q 2023)

AmCad BioMed Corporation Announces Change of the Corporate Governance Officer

AmCad BioMed Corporation to Report Q2, 2024 Results on Aug 08, 2024

AmCad BioMed Corporation has completed a Follow-on Equity Offering in the amount of TWD 230 million.

First quarter 2024 earnings released: NT$0.29 loss per share (vs NT$0.20 loss in 1Q 2023)

AmCad BioMed Corporation has filed a Follow-on Equity Offering in the amount of TWD 350 million.

AmCad BioMed Corporation to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings released: NT$0.85 loss per share (vs NT$1.01 loss in FY 2022)

AmCad BioMed Corporation, Annual General Meeting, Jun 26, 2024

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: NT$0.24 loss per share (vs NT$0.22 loss in 2Q 2022)

New minor risk - Share price stability

AmCad BioMed Corporation Announces Management Changes

AmCad Biomed Corporation Appoints Maureen Chang as Corporate Governance Officer

Less than half of directors are independent

Third quarter 2022 earnings released: NT$0.27 loss per share (vs NT$0.001 profit in 3Q 2021)

Second quarter 2022 earnings released: NT$0.22 loss per share (vs NT$0.16 loss in 2Q 2021)

First quarter 2022 earnings released: NT$0.15 loss per share (vs NT$0.21 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

AmCad BioMed Corporation Appoints Maureen Chang as Spokesperson, Financial Officer and Accounting Officer

Third quarter 2021 earnings released: EPS NT$0.001 (vs NT$0.18 loss in 3Q 2020)

AmCad BioMed Corporation Announces Receiving FDA Approval of AmCad UTdeep Learning Advanced Version

Second quarter 2021 earnings released: NT$0.16 loss per share (vs NT$0.10 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.21 loss per share (vs NT$0.30 loss in 1Q 2020)

Companies Like AmCad BioMed (GTSM:4188) Are In A Position To Invest In Growth

Full year 2020 earnings released: NT$0.67 loss per share (vs NT$0.71 loss in FY 2019)

Full year 2020 earnings released: NT$0.67 loss per share (vs NT$0.71 loss in FY 2019)

AmCad BioMed Corporation, Annual General Meeting, May 21, 2021

New 90-day low: NT$18.55

New 90-day low: NT$18.80

AmCad BioMed (GTSM:4188) Is In A Good Position To Deliver On Growth Plans

Third quarter 2020 earnings released: NT$0.19 loss per share

AmCad BioMed Corporation Announces Board Changes

AmCad BioMed Corporation Announces Resignation of Lee, Chen Chia as Chairperson, Effective November 5, 2020

New 90-day low: NT$19.45

First half earnings released

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi